Background: Breast cancer is the most common female malignancy and the leading cause of cancer mortality in women worldwide. The human epidermal growth factor receptor2 (HER2) is a transmembrane tyrosine kinase receptor that is usually overexpressed in human breast cancers. Stable cell lines heterogeneously overexpressing HER2 are highly required as in vitro models for breast cancer research. T...

Signalling by the insulin receptor substrate (IRS) proteins is critically dependent on the tyrosine phosphorylation of specific binding sites that recruit Src homology 2 (SH2)-domain-containing proteins, such as the p85 subunit of phosphoinositide 3-kinase (PI 3-kinase), the tyrosine phosphatase SHP-2 and the adapter protein Grb2. Here we show that stimulation by insulin of freshly isolated pri...

Although non-insulin-dependent diabetes mellitus (NIDDM) is associated with defects in insulin action, the molecular basis of this resistance is unknown. We studied fibroblasts from a markedly insulin-resistant patient with NIDDM but without acanthosis nigricans. Her fibroblasts were resistant to insulin when alpha-aminoisobutyric acid uptake was measured. Fibroblasts from this patient demonstr...

PD 089828, a novel protein tyrosine kinase inhibitor of a new structural class, the 6-aryl-pyrido-[2,3-d]pyrimidines, was identified by screening a compound library with assays that measured protein tyrosine kinase activity. PD 089828 was found to inhibit human full-length fibroblast growth factor (FGF) receptor-1 (FGFR-1), platelet-derived growth factor (PDGF) receptor beta subunit (PDGFR-beta...

Tyrosine kinase inhibitors are molecules that block various intracellular signaling pathways. Trials with some tyrosine kinase inhibitors showed promising results in thyroid cancer. They are thought to owe their antitumor property mainly to their effect on vascular endothelial growth factor receptor which is important in angiogenesis. Axl is a receptor tyrosine kinase shown to be involved in pr...


 CADTH recommends that Rozlytrek be reimbursed by public drug plans for the treatment of adults with unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without known acquired resistance mutation if certain conditions are met.
 should only to treat patients who previously f...

A human epithelial (HeLa) cDNA library was screened with degenerate oligonucleotides designed to hybridize to highly conserved regions of protein-tyrosine kinases. One cDNA from this screen was shown to contain a putative protein-tyrosine kinase catalytic domain and subsequently used to isolate another cDNA from a human keratinocyte library that encompasses the entire coding region of a 976-ami...

Receptor tyrosine kinases (RTKs) orchestrate embryonic development and tissue homeostasis by controlling key cellular processes like growth proliferation. Consequently, the vast majority of 58 RTKs in humans are linked to cancer or metabolic disorders. For instance, represent known oncogenic drivers (such as EGFR non-small cell lung cancer), contribute hallmarks VEGFR pro-tumor angiogenesis), m...

Protein tyrosine kinases have long been recognized as the most proximal actors in T-cell antigen receptor (TCR) signaling. Three non-receptor tyrosine kinase families (Src, ZAP-70 and Tec) are known to be critical, but a new study now shows that room needs to be made in this pathway for yet another protein tyrosine kinase family - Abl/Arg.

Genetic profiling of non-small cell lung cancer (NSCLC) tissue has identified alterations in a number genes, including c-MET. Dysregulation c-MET, receptor tyrosine kinase mesenchymal epithelial transition factor, is associated with worse prognosis. Therapeutics targeting c-MET such as the antibody drug conjugate (ADC) Telisotuzimab vedotin (Teliso-V) may be benefit. Currently, immunohistochemi...